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Inflammation and caspase activation in long-term renal
ischemia/reperfusion injury and immunosuppression in rats.
Background. We have previously shown the long-term influ-
ence of renal ischemia/reperfusion (I/R) injury and immuno-
suppression on fibrotic genes and apoptosis in a rat model. For
the first time, we have now investigated the effects of I/R and
immunosuppression on inflammation and caspase activation.
Methods. I/R injury was induced in the right kidney and the
left was removed. Cyclosporin (CsA) (10 mg/kg), tacrolimus
(0.2 mg/kg), rapamycin (1 mg/kg), or mycophenolate mofetil
(MMF) (10 mg/kg) was then administered for 16 weeks.
The effects of I/R and immunosuppressants on interstitial
inflammation, interleukin (IL)-1b expression, caspase-1 and
caspase-3 activation, tubulointerstitial damage, and fibrosis
were evaluated.
Results. ED-1+ (a specific rat monocyte/macrophage
marker) cells were mainly localized in the tubulointerstitium
and periglomerular areas and increased in I/R group compared
to controls (P < 0.01). This was further increased by CsA, but
decreased by tacrolimus, rapamycin, or MMF (P < 0.05). The
17 kD active IL-1b remained unchanged, but 35 kD IL-1b pre-
cursor was decreased by rapamycin in comparison with I/R
group (P < 0.05). The 45 kD or 20 kD caspase-1 was increased
by I/R or CsA, respectively, and decreased by rapamycin (P
< 0.05). The 24 kD caspase-3, which proved to be an active
caspase-3 subunit, was increased in I/R and CsA groups and de-
ceased by tacrolimus, rapamycin, or MMF (P < 0.05), but not
32 kD precursor or 17 kD active caspase-3. The activity data
of caspase-1 and caspase-3 exhibited the same trend as West-
ern blotting data. The staining of active caspase-3 was scattered
in kidneys, mainly in tubular and interstitial areas, which was
consistent with that of ED-1+ cells. There was a strong pos-
itive correlation between interstitial inflammation and 24 kD
caspase-3 expression or caspase-3 activity (r = 0.814 or 0.484),
all of which were also closely related with urinary protein (r =
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0.537, 0.529, or 0.517), serum creatinine (r = 0.463, 0.573, or
0.539), tubulointerstitial damage (r = 0.794, 0.618, or 0.712)
and fibrosis (r = 0.651, 0.567, or 0.469), all P < 0.01.
Conclusion. This study shows that the mechanisms of long-
term I/R injury and immunosuppressants treatment include
interstitial inflammation and caspase activation, most clearly
demonstrated by the 24 kD active caspase-3.
Chronic allograft nephropathy is the principal cause
of allograft failure [1, 2]. Many factors are involved in
the progression of chronic allograft nephropathy, includ-
ing immune injury, ischemia/reperfusion (I/R) injury, the
inflammatory response, and immunosuppressant drugs
[2, 3]. I/R injury is especially important in kidney trans-
plantation, being associated with primary nonfunction,
delayed graft function, increased acute rejection, and late
allograft dysfunction [4]. The underlying mechanisms of
I/R injury have been elucidated, including abnormalities
in regional blood flow, endothelial/epithelial cell dysfunc-
tion, inflammation, and tubular obstruction [5]. The ini-
tial ischemic insult may also lead to the up-regulation
of class II major histocompatability complex (MHC)
molecules, thus increasing the immunogenicity of the is-
chemic organ [6]. Although immunity, inflammation, and
other factors have tended to be considered and investi-
gated in isolation, it has become evident that these aspects
are interdependent and may either coexist or act as dis-
tinct entities depending on the time frame and intensity
of I/R injury.
The involvement of inflammatory mediators in the
course of I/R has been extensively addressed, but the
etiology of I/R-induced inflammation remains largely
obscure [4]. Many studies suggest that neutrophil recruit-
ment to the site of injury is a central event in the pathogen-
esis of renal I/R injury [7, 8]. The generation of oxygen
free radicals [9] enhances the local expression of adhe-
sion molecules [10, 11] and promotes neutrophil chemo-
taxis during early reperfusion. The activation of the
complement system [12, 13] is also involved in neutrophil
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influx and I/R damage. Moreover, it has been revealed
that various activated caspases participate in the pro-
cessing of the proinflammatory cytokines, apart from its
well-recognized mission in apoptotic cell death. First,
caspase-1 is a widely accepted inflammatory mediator
because it is involved in the maturation of interleukin
(IL)-1b [14–16] and IL-18 [17, 18], both of which
have been implicated in the pathogenesis of renal I/R
injury. Caspase-3 activation has been recently linked
with inflammation via processing of IL-1b , IL-18, and
macrophage inflammatory protein-2 (MIP-2) [19–21].
Caspase-7 is responsible for processing the endothelial
monocyte-activating polypeptide II (EMAP-II), which is
produced in the early phase of renal I/R injury [4, 22]. Fi-
nally, caspase-11, which activates caspase-1 and caspase-
3, plays a crucial role in inflammation [23].
Therapeutic strategies for the attenuation of I/R in-
jury by abrogating the inflammatory response have
included the use of antibodies against intercellular
adhesion molecule (ICAM)-1 [24], tumor necrosis fac-
tor (TNF)-a [25] or interferon (INF)-c [26], the deple-
tion of complement components [10, 27] or neutrophils
[28], and inhibition of caspases [29]. However, almost
all of these studies were designed to observe the ef-
fects on the acute phase of I/R injury. The long-term
impact of I/R injury and the modern immunosuppres-
sants used for kidney transplantation on inflammation
has been less well studied. The common immunosup-
pressants used in human kidney transplantation are cal-
cineurin inhibitors, cyclosporine A (CsA) and tacrolimus;
a macrolide-triene antibiotic, rapamycin; and a specific
inhibitor of inosine monophosphate dehydrogenase, my-
cophenolate mofetil (MMF). These immunosuppressants
have anti-inflammatory effects via different pathways,
but their precise mechanisms need to be further explored.
Although a model of renal transplantation developing
chronic allograft nephropathy would be the most rele-
vant to the clinical situation, this model, as well as being
technically difficult, would require baseline immuno-
suppression, making it more difficult to assess the
relative contributions of each individual immunosup-
pressant. The I/R rat model, therefore, has been
widely used as an alternative substitute that mim-
ics part of crucial changes occurring in chronic al-
lograft nephroapthy. It has previously been shown
that tacrolimus and rapamycin, but not CsA, pro-
tect against the effects of I/R injury over a 16-week
period [30, 31]. Links with fibrotic genes and their ef-
fects on extracellular matrix turnover [32] and apoptosis
modulating renal tubular cell loss [abstract; Yang B, et al,
J Am Soc Nephrol 13:96, 2002] have been investigated
using this model. In the current study, we have investi-
gated, for the first time, the long-term effects of I/R injury
and immunosuppressants on the degree and distribution
of inflammatory cells; IL-1 and caspase-1 expression and
activity; caspase-3 activation, activity, and localization;
tubulointerstitial damage; and fibrosis. In addition, cor-
relations between measures of inflammation, its possible
mediators and changes in renal function and histology
have been studied.
METHODS
I/R model
The model of renal I/R injury has previously been de-
scribed [30, 31]. Briefly, groups (N = 4 to 6) of male Wistar
rats (300 to 350g) were anesthetized with halothane and
underwent occlusion of the right renal vascular pedicle
for 45 minutes, together with left nephrectomy. This ap-
proach has previously been found to be the longest period
of renal warm ischemia compatible with survival and in-
duce an appropriate degree of renal injury [33]. After
recovery, animals were followed for a period of 16weeks.
Rats were housed at constant temperature (20◦C) and
humidity (45%) on a 12-hour light/dark cycle, fed ad libi-
tum on standard laboratory rat chow, and had free access
to tap water. All the experiments were carried out ac-
cording to the regulations laid down by the Home Office
(Animal Scientific Procedure Act 1986, UK).
Drug administration
After the surgical procedure, microemulsion CsA dis-
solved in pure olive oil (10 mg/kg) (Neoral®) (Novartis
Pharmaceuticals, Sussex, UK), tacrolimus powder dis-
solved in water (0.2 mg/kg) (Prograf®) (Fujisawa Phar-
maceuticals, London, UK), rapamycin liquid (1 mg/kg)
(Rapammune®) (Wyeth Pharmaceuticals, Berks, UK),
MMF (10 mg/kg) (Cellcept®) (Roche Pharmaceuticals,
UK), or drug vehicle was administered orally by gavage
once daily for 16 weeks. The dosage and administration
route of immunosuppressants were chosen based on the
previous studies, the clinical doses for humans and their
side effects, and our own preliminary data [31, 34–36]. An-
imals undergoing sham operation (control), laparotomy
and vascular pedicle dissection, and unilateral nephrec-
tomy only were included as controls.
Assessment of histologic change and renal function
The sections were stained with picro Sirius Red
overnight (0.1% Sirius Red in saturated aqueous picric
acid) to detect tubulointerstitial fibrosis, especially colla-
gens I and III [37, 38]. Rapid dehydration was repeated
with an initial wash of 0.01 N HCl for 2 minutes, and serial
washes of 70% ethanol for 45 seconds followed by 80, 90,
and 100% ethanol for 2 minutes. Slides were cleared with
two washes of xylene and mounted with DPX mountant.
The entire renal cortex of each kidney was semiquantita-
tively analyzed using a previously validated image analy-
sis system on an Apple Macintosh computer system using
the NIH image software (National Institutes of Health,
Bethesda, MD, USA) [39].
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Hematoxylin and eosin–stained sections of kidney
were also semiquantitatively graded for tubulointerstitial
damage (tubular dilation or atrophy and interstitial ex-
pansion with edema, inflammatory infiltrate or fibrosis)
based on a scale of 0 to 3. The normal cortical tubulointer-
stitium scored 0; mild tubulointerstitial damage affecting
up to 25% of an objective field at ×200 magnification
scored 1; moderate tubulointerstitial damage affecting
25% to 50% of the field scored 2; and severe tubuloint-
erstitial damage exceeding 50% of the field scored 3. The
examiners were blinded to the treatment groups and the
randomly selected 12 cortical fields were scored for each
animal and the mean score attributed to the animal [40].
Blood obtained at the time of sacrifice was used to
measure serum creatinine levels as an indication of re-
nal function. 24-hour urinary protein was determined by
the Bradford method as a marker of renal damage. At
the end of the 16-week study period, rats were reanes-
thetized and the right kidney was removed immediately.
Renal cortical tissue was fixed in 10% (wt/vol) neutral
buffered formalin and paraffin-embedded for histologic
and immunohistochemical examination, or snap frozen
and stored in liquid nitrogen for total protein analysis.
Evaluation of renal inflammation by ED-1
immunostaining
Renal inflammation was evaluated by ED-1 (a spe-
cific rat monocyte/macrophage marker) immunostaining
on paraffin-embedded tissues using a Dako ChemMate
EnVisionTM Detection Kit (Dako, Glostrup, Denmark).
Sections were pretreated with 0.125% (wt/vol) trypsin at
37
◦
C for 10 minutes. A monoclonal mouse antirat ED-
1 antibody (Serotec Ltd., Oxford, UK) at 1:50 dilution
was applied overnight at 4
◦
C. Thereafter, antibody bind-
ing was revealed using the peroxidase/diaminobenzidine
(DAB) from the Dako kit. Sections were counterstained
with hematoxylin and mounted in glycergel (Dako). Neg-
ative control sections were incubated with normal mouse
IgG at the same protein concentration of primary anti-
body. Renal inflammation was evaluated by a semiquan-
titative analysis based on calculating the percentage of
ED-1+ cells area fraction (both glomeruli and tubu-
lointerstitium) in 20 fields at ×400 magnification using
computer-aided software.
Measurement of tissue IL-1b, caspase-1, caspase-3,
or b-actin protein
Ten percent (wt/vol) kidney cortex homogenate was
prepared and 20 lg of protein was separated on a 15%
(wt/vol) polyacrylamide denaturing gel and electroblot-
ted onto Hybond C membrane (Amersham Life Science,
Buckinghamshire, UK) [41]. This was blocked with 5%
(wt/vol) milk and probed with a polyclonal rabbit anti-
rat full-length IL-1b (1:1000 dilution) (NIBSC, Potters
Bar, UK), caspase-1 (1:500 dilution) (Upstate Biotech-
nology, Milton Keynes, UK), caspase-3 (1:1000 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) an-
tibody, or a monoclonal mouse anti-b-actin antibody
(1:5000; dilution Insight Biotechnology, Middlesex, UK)
[42]. The antibody binding was revealed using an antirab-
bit (caspase-3) or mouse (b-actin) peroxidase conjugate
(Dako) or antirabbit (IL-1b and caspase-1) ABC Elite
Kit (Vector Laboratories, Peterborough, UK) diluted
at 1:1000 and the enhanced chemiluminescence (ECL)
detection system (Amersham Life Science). Developed
films were semiquantitatively analyzed by scanning vol-
ume density using a Bio-Rad GS-690 densitometer and
Molecular Analyst version 4 software (Bio-Rad Labora-
tories Ltd., Hertfordshire, UK). Optical volume density
value for IL-1b , caspase-1, or caspase-3 was corrected
for loading using b-actin expression. Results were ex-
pressed as the percentage of the average control volume
density. The size of target protein was determined by
comparison with protein molecular weight markers (Bio-
Rad Laboratories Ltd.) using the same analysis package
[41, 43, 44].
Caspase-1 and caspase-3 activity assays
The activities of caspase-1 and caspase-3 were de-
tected by a modified Fluorometric CaspACETM As-
say System (Promega, Southampton, UK) using 100 lg
of protein extracted from renal tissues [41]. This as-
say is based on the ability of caspase-1 or caspase-3 to
cleave the fluorogenic substrate of Ac-YVAD-7-amino-
4-methyl coumarin (AMC) or Ac-DEVD-AMC. The
specificity of the assay was determined using the caspase-
1 inhibitor Ac-YVAD-CHO or caspase-3 inhibitor Ac-
DEVD-CHO. The fluorescence of the reaction was
monitored at an excitation wavelength of 360 nm and an
emission wavelength of 460 nm using an Mx 4000TM Mul-
tiplex Quantitative PCR System (Stratagene, Foster City,
UK). The fluorescence intensity was calibrated with stan-
dard concentrations of AMC and caspase-1 or caspase-3
activity was expressed as picomole AMC liberated per
minute per microgram protein at 30◦C.
Electroelution
Protein homogenates of the kidney cortex were fur-
ther analyzed by electroelution using a miniwhole gel
eluter system (Bio-Rad), which allows the simultaneous
electroelution of multiple protein bands separated by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) into 14 narrow chambers [45]. Pro-
tein (100 lg) from the kidney of rat number 6 in the
CsA group, which had the highest caspase-3 activity, was
loaded into each well of a 15% SDS-PAGE gel. The pro-
teins in the SDS-PAGE gel was then electroeluted into
Tris/boric acid buffer for 20 minutes (the eluter acts as an
electrodialyzer removing SDS from protein and leaving
them in a nontoxic physiologic buffer). A total of 54 lL
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eluates from all chambers were analyzed for caspase-3
activity as described above. Two samples of the original
protein homogenate and pure caspase-3 enzyme (Sigma,
Dorset, UK) were used as positive controls. Fifteen mi-
croliter eluates were again resolved by SDS-PAGE and
stained with brilliant blue or processed for subsequent
Western blotting with the antibody against full-length
caspase-3.
Immunostaining of active caspase-3
The localization of active caspase-3 protein was de-
tected by immunostaining of paraffin-embedded tissues.
An affinity-purified rabbit anti-17 kD active caspase-3
antibody (R&D Systems Europe, Ltd., Abingdon, UK)
at 1:400 dilution was applied for 1 hour at 37◦C. There-
after, antibody binding was revealed using the per-
oxidase/DAB from the Dako ChemMate EnVisionTM
Detection Kit. Sections were counterstained with hema-
toxylin and mounted in glycergel. Negative control sec-
tions were incubated with normal mouse IgG at the same
protein concentration of the primary antibody.
Statistical analysis
Results are expressed as mean ± standard error of the
mean (SEM). The statistical difference was assessed by
a signal factor analysis of variance (ANOVA) and the
Student t test. The correlation between parameters was
determined by linear correlation and multiple regression
analyses using SPSS software (SPSS Inc., Chicago, IL,
USA). P < 0.05 was considered to be significant [44].
RESULTS
I/R injury, immunosuppressant treatment,
and inflammation
The effects of I/R and immunosuppressants on renal
inflammation were evaluated by computerised histomor-
phometry of ED-1 immunostaining. There were very few
ED-1+ cells inside glomeruli and interstitium in control
kidneys (Fig. 1A). However, ED-1+ cells were dramati-
cally increased in I/R kidneys and localized mainly in the
periglomerular, peritubular, expanded interstitial areas
(Fig. 1B), and tubular lumens (Fig. 1C).
I/R injury (0.37 ± 0.06%) (Fig. 1E) increased inflam-
mation compared to the controls (sham control 0.07 ±
0.02%) (unilateral nephrectomy 0.08 ± 0.01%) (P < 0.01)
(Fig. 1D and J). The number of ED-1+ cells in the uni-
lateral nephrectomy group was almost identical to that
in the sham control group (Fig. 1J). Therefore, inflamma-
tion can be attributed to I/R injury rather than unilateral
nephrectomy. CsA (0.63 ± 0.08%) (P < 0.05) (Fig. 1F and
J) enhanced the infiltration of inflammatory cells into the
interstitial area compared to the I/R group. In contrast,
inflammatory cell infiltration was reduced by administra-
tion of the other immunosuppressants (tacrolimus 0.17 ±
0.04%) (rapamycin 0.102 ± 0.03%) (MMF 0.17 ± 0.02%)
(P < 0.05 or 0.01) (Fig. 1G to J) when compared to the
I/R or CsA group.
Effect of I/R and immunosuppressants on the protein
expression of IL-1b, caspase-1, and caspase-3
The protein expression of IL-1b , caspase-1, and
caspase-3 in kidney tissues was determined by Western
blotting. The 42 kD b-actin was used to control sample in-
tegrity and loading in each lane on the same membrane
for detection of IL-1b , caspase-1, or caspase-3 (Figs. 2
to 4). There were no significant differences between the
studied groups.
The 35 kD IL-1b precursor was increased in the I/R
group (153.5 ± 27.7%) compared to the controls (con-
trol 100.0 ± 22.7% and unilateral nephrectomy 96.2 ±
22.8%), but this difference did not reach statistical signif-
icance. In comparison with the I/R group, only rapamycin
significantly decreased the expression of 35 kD IL-1b
(68.5 ± 8.2%) (P < 0.05), whereas CsA (135.6 ± 16.0%),
tacrolimus (134.7 ± 19.4%), or MMF (101.6 ± 23.3%)
had no significant effects (Fig. 2A). Seventeen kD ac-
tive IL-1b remained statistically unchanged, although I/R
(126.7 ± 22.5%) and all four immunosuppressants (CsA
141.7 ± 18.3%; tacrolimus 139.7 ± 19.3%; rapamycin
129.2 ± 16.5%, or MMF 130.0 ± 12.3%) numerically
increased its expression when compared to the controls
(control 100.0 ± 18.7% and unilateral nephrectomy 98.8
± 25.6%) (Fig. 2B).
A 45 kD caspase-1 precursor was significantly in-
creased in the I/R group (125.8 ± 4.5%) compared to
sham control (100 ± 8.4%) (P < 0.05). Rapamycin signif-
icantly decreased caspase-1 precursor (83.0 ± 9.6%) (P <
0.01), but the other drugs had no such effect (CsA 126.2 ±
4.0%; tacrolimus 113.0 ± 3.2%; or MMF 114.6 ± 9.1%)
(Fig. 3A). There was only a marginal difference between
the I/R and unilateral nephrectomy group (96.4 ± 17.2)
(P = 0.08). Although 20 kD active caspase-1 did not
change significantly in the I/R group compared to the
controls (control 99 ± 16.2% and unilateral nephrec-
tomy 95.2 ± 25.0%), it was significantly increased by
CsA (130.4 ± 5.6%) and decreased by rapamycin (66.8 ±
12.1%) (both P < 0.05). Tacrolimus (93.8 ± 13.5%) and
MMF (86.1 ± 1.6%) had no significant effect on 20 kD
active caspase-1 expression (Fig. 3B).
The 32 kD caspase-3 precursor increased in the I/R
group (157 ± 13%) compared to controls (control 100 ±
13% and unilateral nephrectomy 95 ± 15%) (both P <
0.05) (Fig. 4A). However, compared to the I/R group, the
various immunosuppressants did not significantly affect
its expression (CsA 191 ± 39%, tacrolimus 206 ± 34%,
rapamycin 134 ± 18%, and MMF 188 ± 32%). The 29 kD
processing intermediate was also present in the kidneys
of all groups (Fig. 4). Interestingly, the 24 kD band, rep-
resenting active caspase-3, was increased by I/R injury
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Fig. 1. Endothelin-1 (ED-1+) cells in different compartments of kidneys and staining profiles in various experimental groups. ED-1+ cells were
detected in the glomerulus (A), peri glomerular areas, peritubular areas, expanded interstitial areas (B), and tubular lumen (C, arrows) at ×400
magnification. ED-1+ cells were scattered in the controls [control (sham-operated) and unilateral nephrectomy (UN)]; (D) and dramatically
increased in ischemia/reperfusion (I/R) kidneys (E), and were further increased by cyclosporine A (CsA) treatment (F), mainly in interstitial areas,
but decreased by tacrolimus (Tac) (G), rapamycin (Rap) (H), and mycophenolate mofetil (MMF) (I) treatment at ×200 magnification. Histogram
(J) shows the ED-1+ staining as a percentage of the whole area in the kidneys of various groups using computer aided semiquantitative analysis.
Data represents mean ± SEM (N = 4 to 6). ∗P < 0.05; ∗∗P < 0.01.
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Fig. 2. Expression of interleukin(IL)-1b protein detected by Western blot analysis. Sample immunoblots showed 35 kD precursor and 17 kD active
subunit of IL-1b . A 42 kD band of b-actin was detected to show the loading of samples in each lane. Histogram data represent the result of volume
density analysis 35 kD (A) and 17 kD (B) IL-1b using b-actin to correct for loading. Data represent the mean percentage change in volume density
compared to the average control value (mean ± SEM) (N = 4 to 6). ∗P < 0.05; ∗∗P < 0.01. Abbreviations are: control, sham-operated; UN, unilateral
nephrectomy; I/R, ischemia/reperfusion; CsA, cyclosporine A; Tac, tacrolimus; Rap, rapamycin; MMF, mycophenolate mofetil.
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Fig. 3. Caspase-1 Western blots revealed 45 kD precursor and 20 kD active subunit. A 42 kD band of b-actin was detected to show the loading of
samples in each lane. Histogram data represent the result of volume density analysis of 45 kD (A) and 20 kD (B) caspase-1 using b-actin to correct
for loading, and the detection of caspase-1 activity (C). Data represent the mean percentage change in volume density compared to the average
control value (mean ± SEM) (N = 4 to 6). ∗P < 0.05; ∗∗P < 0.01. Abbreviations are: Control, sham-operated; UN, unilateral nephrectomy; I/R,
ischemia/reperfusion; CsA, cyclosporine A; Tac, tacrolimus; Rap, rapamycin; MMF, mycophenolate mofetil.
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Fig. 4. Expression of caspase-3 protein detected by Western blot analysis. Immunoblots showed a 32 kD band, representing the precursor of
caspase-3; a 29 kD band, representing processing intermediate of caspase-3; 17 kD and 24 kD bands, representing the caspase-3 active subunits.
The expression of 42 kD b-actin demonstrates the equal loading of samples in each lane. Histogram data represent the result of volume density
analysis 32 kD (A), 24 kD (B), and 17 kD (C) caspase-3 using b-actin to correct for loading. Data represent the mean percentage change in volume
density compared to the average control value (mean ± SEM) (N = 4 to 6). ∗P < 0.05; ∗∗P < 0.01. Abbreviations are: control, sham-operated; UN,
unilateral nephrectomy; I/R, ischemia/reperfusion; CsA, cyclosporine A; Tac, tacrolimus; Rap, rapamycin; MMF, mycophenolate mofetil.
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Fig. 5. Caspase-3 activity in kidney tis-
sues assayed by the fluorometric substrate
cleavage. This measurement was repeated
three times and data represents mean ±
SEM (N = 4 to 6). ∗P < 0.05; ∗∗P <
0.01. Abbreviations are: control, sham-
operated; UN, unilateral nephrectomy; I/R,
ischeemia/reperfusion; CsA, cyclosporine A;
Tac, tacrolimus; Rap, rapamycin; MMF, my-
cophenolate mofetil.
(256 ± 35%) compared to the controls (control 100 ±
26%) (P < 0.01) (unilateral nephrectomy 155 ± 9%) (P <
0.05) (Fig. 6B). CsA led to a further increase (382 ± 66%),
but the difference did not reach statistical significance.
Tacrolimus (134 ± 11%) (P < 0.05), rapamycin (31 ± 4%)
(P < 0.01), and MMF (63 ± 6%) (P < 0.01) significantly
decreased the expression of 24 kD caspase-3 compared
to the I/R or CsA group (all P < 0.01). The 17 kD band,
another caspase-3 active subunit, demonstrated similar
trends to the 24 kD caspase-3 (I/R 407±118%; CsA 621±
252%; tacrolimus 267 ± 65%; rapamycin 244 ± 76%; and
MMF 220 ± 48%), but other than an increase in the uni-
lateral nephrectomy group (370 ± 117%) compared to
the control (100 ± 15%) (P < 0.01), these changes did
not reach statistical significance (Fig. 4C).
Effect of I/R and immunosuppressants on caspase-1
and caspase-3 activity
To confirm the expression of caspase-1 and caspase-3
detected by Western blotting, we measured caspase-1
and caspase-3 activity. There was an increased trend in
caspase-1 activity in the most of experimental groups over
the control except for the rapamycin group, which showed
a decrease, but these did not reach statistical signifi-
cance (control 0.0023 ± 0.0002, unilateral nephrectomy
0.0028 ± 0.0004, I/R 0.0037 ± 0.007, CsA 0.0039 ± 0.0006,
tacrolimus 0.0041 ± 0.0014, and rapamycin 0.0029 ±
0.0004) (Fig. 3C). Caspase-3 activity was significantly in-
creased in the I/R kidneys (0.039 ± 0.011) (Fig. 5) com-
pared to the control group (0.009 ± 0.003) (P < 0.05),
but this increase only reached a marginal statistical sig-
nificance when compared to the unilateral nephrectomy
group (0.011 ± 0.004) (P = 0.06). The elevated caspase-3
activity in the I/R kidneys was reduced in the rapamycin-
treated group (0.010 ± 0.005) (P < 0.05), but did not sig-
nificantly change in the CsA (0.042 ± 0.014), tacrolimus
(0.035 ± 0.018), or MMF (0.025 ± 0.009) treatment group.
There was also a marginal difference between rapamycin
and CsA treatment (P = 0.08). The specific and competi-
tive tetrapeptide inhibitor of caspase-1 Ac-YVAD-CHO
or caspase-3 Ac-DEVD-CHO, almost fully inhibited the
caspase-1 or 3 activity, demonstrating the specificity of
the assay (data not shown).
Electroelution of whole SDS PAGE gels
In order to verify that the 24 kD band illustrated in
Western blot is an active caspase-3, proteins resolved by
SDS-PAGE were electroeluted into 14 chambers. The
eluate from chamber 6 showed the highest caspase-3 ac-
tivity and the eluate from chamber 10 revealed weaker
caspase-3 activity (Fig. 6A). The SDS-PAGE gel loading
with eluates from all chambers and staining with brilliant
blue revealed the size of the protein in chamber 6 to be
of the order of 24 kD. The activity detected in chamber
10 could be due to the 17 kD caspase-3 (Fig. 6B). This
was further confirmed by Western blotting using an an-
tibody to full-length caspase-3 (Fig. 6C). These experi-
ments strongly indicate that the 24 kD band is an active
caspase-3 protein.
Localization of active caspase-3
The distribution of active caspase-3 protein in kidney
sections was revealed by immunostaining. The positive
staining was scattered in kidneys, especially in glomeru-
lar areas (Fig. 7A). There was more staining in the tubu-
lar (Fig. 7B) and interstitial areas (Fig. 7C), and some
positively stained cells showing the morphologic changes
of apoptosis (such as shrunken cell with condensed nu-
cleus) (Fig. 7B). The positive stained cells were seen in
Yang et al: Inﬂammation, caspase, and immunosuppressants in renal I/R injury 2059
Fig. 6. Caspase-3 activity in electroeluted homogenate samples. Caspase-3 activity was highest in chamber 6 and some weaker activity was detected
in chamber 10. 100 lg protein of kidney homogenate from rat number 6 of the cyclosporine A (CsA) group and rat number 4 of the mycophenolate
mofetil (MMF) group, and 44 ng or 11 ng protein of pure caspase-3 enzyme were used as positive controls (A). Electroeluted samples were resolved
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and stained with brilliant blue. The result showed the size of protein
in eluate 6 to be of the order of 24 kD as indicated by an arrow and the protein from eluate 10 to be of the order of 17 kD (B). These data were
further corroborated by Western blotting using the antibody to whole caspase-3 (C).
the tubular lumen as well (Fig. 7D). There was no specific
staining in negative control sections.
Renal function and histologic findings
Extracellular matrix deposition in the kidney was stud-
ied by Sirius Red staining. The dye molecule intercalates
with the tertiary groove in the structure of collagen types
I and III and presents a pink color (Fig. 7E) under white
light, and is strongly birefringent (Fig. 7F) when observed
under polarized light. Sirius Red staining was mainly lo-
cated in the tubulointerstitium rather than the glomeru-
lar interstitium (Fig. 7E and F). As shown in Figure 8A,
it was significantly increased in the I/R (1.04 ± 0.12) or
CsA group (1.30 ± 0.18) compared to controls (control
0.51 ± 0.04 and unilateral nephrectomy 0.34 ± 0.07) (both
P < 0.01). Animals treated with tacrolimus (0.61 ± 0.04),
rapamycin (0.34±0.08), or MMF (0.82±0.08) had signifi-
cantly lower staining level than both I/R and CsA-treated
animals (all P < 0.05).
In the majority of animals, tubulointerstitial damage
was presented as tubular dilation and interstitial inflam-
matory infiltrate and fibrosis. There was no extensive
tubular atrophy and the score of tubulointerstitial dam-
age was mainly between mild to moderate (Fig. 8B). The
tubulointerstitial damage was significantly increased in
the I/R group (0.76 ± 0.15) compared to controls (control
0.04 ± 0.01 and unilateral nephrectomy 0.09 ± 0.02) (both
P < 0.01). CsA increased the tubulointerstitial damage
score when compared to the I/R group, but there was no
statistical difference. Rats in the rapamycin (0.18 ± 0.05),
tacrolimus (0.53 ± 0.20), or MMF (0.45 ± 0.09) group had
less tubulointerstitial damage than the I/R animals, only
rapamycin treatment showed statistical significance (P <
0.01). However, in comparison with the CsA group, ra-
pamycin or MMF (both P < 0.01) significantly decreased
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Fig. 7. Localization of active caspase-3 protein and extracellular matrix deposition. Active caspase-3–positive cells were showed in the glomerulus
(A), tubular area (B), expanded interstitial area (C), and tubular lumen (D, arrows) at ×400 magnification. The positive stained area of Sirius Red
staining presented a pink color under white light (E) and was strongly birefringent under polarized light (F) at ×200 magnification.
the tubulointerstitial damage, but tacrolimus (P = 0.06)
just reached marginal significance.
As we have previously shown, serum creatinine
(lmol/L) (Fig. 9A) was significantly increased in the
unilateral nephrectomy group (65 ± 4.4) in contrast to the
control (49.8 ± 4.1) (P < 0.05). The I/R (88.8 ± 7.0) injury
or CsA (88.8 ± 6.8) treatment further raised the level of
serum creatinine compared to controls (P < 0.05 or 0.01).
Animals treated with tacrolimus (61.4 ± 5.5), rapamycin
(61.0 ± 2.4), or MMF (64 ± 5.8) had significantly lower
serum creatinine level than both I/R and CsA-treated an-
imals (all P < 0.05). Urinary protein (mg/mL) (Fig. 9B)
excretion was also significantly increased in the I/R group
(25.0 ± 5.3) in comparison with controls (control 7.9 ±
1.2 and unilateral nephrectomy 8.0 ± 0.9) (P < 0.05). The
CsA group demonstrated a higher urinary protein excre-
tion than the I/R group, but this only reached marginal
statistical significance (59.1 ± 16.1) (P = 0.07). Rats in
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Fig. 8. Changes of Sirius Red staining (A)
and tubulointerstitial damage (B) in differ-
ent experiment groups. Data are expressed
as mean ± SEM (N = 4 to 6). ∗P < 0.05;
∗∗P < 0.01. Abbreviations are: control, sham-
operated; UN, unilateral nephrectomy; I/R, is-
chemia/reperfusion; CsA cyclosporine A; Tac,
tacrolimus; Rap, rapamycin; MMF, mycophe-
nolate mofetil.
the rapamycin group (13.9 ± 6.1) (P < 0.05) had signif-
icantly less urinary protein excretion than I/R animals,
but the lower level in the tacrolimus (16.4 ± 4.2) or MMF
(15.8 ± 5.8) group did not reach statistical significance.
However, in comparison with the CsA group, tacrolimus
and rapamycin (P < 0.05), but not MMF (P = 0.08), sig-
nificantly decreased urinary protein excretion.
Correlation between inflammation, apoptosis, caspase-3
protein expression, and renal function
There was a positive correlation between interstitial
inflammation and 35 kD IL-1b or 45 kD caspase-1 (r =
0.406 and 0.405, respectively) (P < 0.05), but not for
17 kD IL-1b or 20 kD caspase-1 (Table 1). A strong
positive correlation was revealed between interstitial in-
flammation and the 24 kD caspase-3 or caspase-3 activ-
ity (r = 0.814) (Fig. 10A) (r = 0.484) (Fig. 10B) (P <
0.01), respectively, all of which were also correlated with
the change in serum creatinine (r = 0.463) (Fig. 10C)
(r = 0.573) (Fig. 10D) (r = 0.539) (P < 0.01), respec-
tively, and urinary protein (r = 0.537) (Fig. 10C) (r =
0.529) (Fig. 9D) (r = 0.517) (P < 0.01), respectively,
and the level of tubulointerstitial damage (r = 0.794)
(Fig. 10E) (r = 0.618) (Fig. 10F) (r = 0.712) (P <
0.01), respectively, and fibrosis (r = 0.651) (Fig. 10E) (r =
0.567) (Fig. 10F) (r = 0.469) (P < 0.01), respectively. To
a lesser extent, interstitial inflammation was correlated
with 32 kD (r = 0.457) (P < 0.01) and 17 kD (r = 0.341)
(P < 0.05) caspase-3 protein expression. The expression
of 35 kD IL-1b was also linked with 45 kD casapse-1
(r =0.466) (P<0.01) and 24 kD caspase-3 (r =0.386) (P<
0.05). Multiple regression analyses showed that caspase-
3 activity was more related to 24 kD caspase-3 (stan-
dardized b coefficients = 0.435) (P < 0.05) compared
to 32 kD (standard b coefficients = 0.361) (P < 0.05) or
17 kD caspase-3 (standard b coefficients = 0.141) (P >
0.05). The 24 kD caspase-3 had the strongest associa-
tion with the change in inflammation (standard b coeffi-
cients = 1.093) (P < 0.01) when compared to either the
32 kD (standard b coefficients = 0.183) (P = 0.074) or
17 kD caspase-3, 45 kD or 20 kD caspase-1 and 35 kD or
17 kD IL-1b (standard b coefficients = 0.241) (P = 0.056).
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Fig. 9. Changes of serum creatinine (A) and
urinary protein (B) in different experiment
groups. Data are expressed as mean ± SEM
(N = 4 to 6). ∗P < 0.05; ∗∗P < 0.01. Abbrevia-
tions are: control, sham-operated; UN, unilat-
eral nephrectomy; I/R, ischemia/reperfusion;
CsA, cyclosporine A; Tac, tacrolimus; Rap, ra-
pamycin; MMF, mycophenolate mofetil.
DISCUSSION
I/R injury is an important factor influencing both early
allograft function and long-term graft survival following
kidney transplantation. The inflammation involved in the
progression of I/R injury may be mediated by a variety of
inflammatory mediators, neutrophil infiltration, caspase
activation, and the occurrence of apoptosis [4, 29]. We
have previously reported that the immunosuppressants
tacrolimus and rapamycin protect against the long-term
effects of I/R injury in a rat model and have elucidated
the mechanisms underlying the deposition of extracellu-
lar matrix [30–32] and the deletion of renal cells by apop-
tosis [abstract; Yang B, et al, J Am Soc Nephrol 13:96,
2002]. However, the precise mechanisms of I/R injury are
far from clear and the effects of immunosuppressants on
renal I/R injury have not been fully defined. The conse-
quent events after I/R involve not only an early but also a
late inflammatory response (lasting several weeks), which
is of particular relevance to chronic allograft reject, but
has been poorly elucidated thus far [4]. For the first time,
using this 16-week-long model, we have further explored
the protein expression of possible inflammatory media-
Table 1. Correlation matrix showing the r value derived from a linear
correlation analysis
Inflammation 24 kD Caspase-3
r value (ED-1 staining) Caspase-3 activity
32 kD Caspase-3 0.457b 0.194 0.438b
24 kD Caspase-3 0.814b 0.532b
17 kD Caspase-3 0.314a 0.672b 0.275
Caspase-3 activity 0.484b 0.532b
45 kD Caspase-1 0.405a 0.470b 0.400a
20 kD caspase-1 0.285 0.349a 0.184
35 kD Interleukin-1b 0.406a 0.386a 0.313
17 kD Interleukin-1b 0.223 0.135 0.236
Serum creatinine 0.463b 0.537b 0.539b
Urinary protein 0.537b 0.529b 0.517b
Tubulointerstitial damage 0.794b 0.618b 0.712b
Fibrosis (Sirius Red staining) 0.651b 0.567b 0.469b
ED-1 is endothelin-1. Correlation matrix showing the r value derived from a
linear correlation analysis.
aP < 0.05; bP < 0.01.
tors IL-1b , caspase-1, and caspase-3, and investigated the
long-term effects of I/R and immunosuppressants on the
development of inflammation and the associated changes
in renal function and morphologic structure.
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Fig. 10. Correlation between endothelin-1 (ED1+) cells, 24 kD caspase-3 protein or activity and other parameters. (A) ED1+ cells vs. the protein
expression of 24 kD caspase-3. (B) ED1+ cells vs. caspase-3 activity. (C) ED1+ cells vs. serum creatinine and urinary protein. (D) 24 kD caspase-3
protein vs. serum creatinine and urinary portiein. (E) ED1+ cells vs. tubulointerstitial damage and Sirus Red staining. (F) 24 kD caspase-3 protein
vs. tubulointerstitial damage and Sirus Red staining in the kidneys of various groups.
We have found that I/R induced a significant increase
of ED-1+ cells that localized mainly in the tubuloint-
erstitium and periglomerular areas. Different immuno-
suppressants had opposite impacts on I/R associated
inflammation. CsA further increased the infiltration of
ED-1+ cells, but tacrolimus, rapamycin, and MMF de-
creased the number of ED-1+ cells. The inflammatory
molecule IL-1b provides a possible mediator of the
change in ED-1+ cells induced by I/R injury or immuno-
suppressants. This would be supported by the finding that
the 35 kD IL-1b was numerically increased by I/R and sig-
nificantly decreased by rapamycin treatment. It may be
that there was simultaneous activation and consumption
of IL-1b during the time course of I/R injury. This could
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lead to continuous cleavage of IL-1b precursor and so
maintain the overall level of 17 kD active IL-1b in differ-
ent groups.
We also showed a significant increase in 45 kD
caspase-1 precursor in the I/R group and 20 kD ac-
tive caspase-1 in the CsA group, both of which were
significantly decreased by rapamycin. Caspase-1 is a
member of caspase family of cysteine proteases and
plays an important role in the maturation of proin-
flammatory cytokines [46, 47]. For instance, caspase-1
[IL-1b–converting enzyme (ICE)] is involved in the
processing of pro-IL-1b and IL-18 [14–18] and all of
these molecules have been implicated in the pathogen-
esis of renal I/R injury [16, 18]. Caspase-1 knockout mice
treated with lipopolysaccharide have a blunted IL-1b
response [48] and reduced ischemic brain injury [49].
In this model, there may be a simultaneous activation
and consumption of caspase-1 in the I/R or immuno-
suppressant treated groups. Once the consumption of
active caspase-1 was inhibited by rapamycin, the in-
creased caspase-1 precursor also reduced. This contin-
uous consumption of active caspase-1 may have been
involved in the processing of IL-1b or other biologic func-
tion such as its engagement in apoptosis. It has been sug-
gested that changes in IL-1b protein can occur through
the activation of caspase-1 [14–16] and active IL-1b could
in turn contribute to renal inflammation, although we
cannot categorically confirm or rule out a direct link be-
tween the activation of caspase-1 and IL-1b in this study.
The caspase-1 activity assay, however, did not show sig-
nificant differences between any groups, which might in-
dicate at least that caspase-1 was not a major player in
this model.
On the other hand, 20 kD active caspase-1 or 17 kD ac-
tive IL-1b was not significantly increased in the I/R group
compared to the controls and neither of them was di-
rectly correlated with the interstitial inflammation though
their precursors were. This may indicate that activated
caspase-1 and its inflammatory product are involved in,
but not key factors for, the induction of inflammation
in this long-term renal I/R injury. This is consistent with
data from the acute renal I/R study (45 minutes renal is-
chaemia followed by 24 hours reperfusion) carried out by
Daemen et al [50] using caspase-1−/− and caspase-1+/+
mice. Therefore, other activated caspases and inflamma-
tory mediators, other than caspase-1 and IL-1b , are likely
to be more prominently involved in this model.
The activation of caspase-3 was evident in this model.
As another important member of the caspase family, it oc-
cupies a critical position in the signal transduction cascade
associated with immune responses, apoptosis, and inflam-
mation. Active caspase-3 is also responsible for the matu-
ration of some proinflammatory mediators, such as IL-1b ,
IL-18, and MIP-2 [19–21]. The 32 kD caspase-3 precur-
sors require two proteolytic cleavage events to become
functionally active enzymes. The removal of NH2 termi-
nal prodomain generates a 29 kD processing intermediate
that is subsequently cleaved into 17 and 12 kD subfrag-
ments, which then heterodimerize to form activated pro-
tease [51–54]. However, other active fragments, such as 18
to 20 kD, have been reported as well [55–59]. The efficacy
of full-length caspase-3 antibody has also been approved
in our previous studies. This antibody was able to bind 17
and 12 kD recombinant human caspase-3 proteins, 20 kD
band in human renal tissues, and 32, 29, 24, and 17 kD
bands in rat renal tissues and cells [41, 43, 44, 60]. In this
study we have shown for the first time that the 24 kD
caspase-3, an active subunit of caspase-3 that is specific
for the species of rat [41, 43], was significantly increased
in the I/R and CsA groups but deceased by tacrolimus,
rapamycin, or MMF at the end point of 16 weeks. This
result was consistent with the change trend in caspase-3
activity. Analysis of the electroeluates not only confirmed
that the 24 kD protein was an active subunit of caspase-3,
but also demonstrated that the 24 kD caspase-3, rather
than the 17 kD protein, predominantly contributed to
the activity of caspase-3. The 24 kD caspase-3 was the
molecule that most closely associated with the changes
of caspase-3 activity in comparison with the 32 kD and
17 kD caspase-3. Similarly, the 24 kD caspase-3 correlated
with episodes of inflammation when compared to 32 kD
or 17 kD caspase-3, 45 kD or 20 kD caspase-1, and 35 kD
or 17 kD IL-1b . This may indicate that 24 kD caspase-3,
rather than the other isoforms of caspase-3 or caspase-1,
was predominantly involved in the progression of inflam-
mation, as well as being involved in the apoptosis per se,
such as processing proinflammatory mediators [19–21] or
cleavage of calpastatin to activate calpain [61, 62]. The in-
flammation driven by the increase of 24 kD caspase-3 may
be a crucial mediator directly linked with the changes in
renal function and structure or the nephrotoxic effect of
CsA that was characterised by interstitial inflammation
and fibrosis, which was well documented [61–63].
The immunostaining of active caspase-3 was scattered
in kidneys and was mainly localized in tubular and in-
terstitial areas. This was consistent with the distribu-
tion of ED-1+ cells. Although the identity of the cells
staining positive with active caspase-3 antibody cannot
be defined, they could be, according to their location,
both tubular and inflammatory cells. The co existence of
active caspase-3–positive cells and ED-1+ cells in the in-
terstitial areas of the kidney appears to imply the involve-
ment of active caspase-3 in inflammation. Some active
caspase-3–stained cells exhibit the morphologic changes
of apoptosis especially in tubular areas indicating their
involvement in apoptosis. In addition, the staining pat-
tern of active caspase-3 was different to that of full-length
caspase-3 in our previous study, which had wider staining
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areas including normal tubular and medullary areas and
rare apoptotic morphologic features [43]. This revealed,
therefore, that the localization of caspase-3 active form
is more actively to be linked with its biologic functions
such as in inflammation and apoptosis.
Furthermore, the effect of caspase-3 on inflammation
may link with calpain, another cysteine protease, which
plays a pivotal role in ischemic injury to liver, heart,
brain, and kidney [66, 65]. Calpain inhibitor-1 reduces
renal dysfunction and injury associated with I/R [66].
Calpain activation has been associated with the down-
regulation and cleavage of calpastatin, a calpain inhibitor,
by caspase-3 and caspase inhibitor Z-D-DCB normalized
these changes [64]. The relationship between caspase-3
and calpain, and the effect of immunosuppressant on cal-
pain in the long-term renal I/R injury model warrants
further investigation.
Different immunosuppressants had varying degrees
of effect on inflammation in this long-term rat I/R in-
jury model. CsA, tacrolimus, and MMF dosages were
similar to those used in the clinical setting, whereas
the rapamycin dosage was approximately tenfold higher.
Rather than reducing the inflammatory effects of I/R,
CsA caused further inflammation, in contrast with the
other agents. A comparison of CsA with tacrolimus, ra-
pamycin, or MMF also demonstrated other differences
with regard to the expression of 24 kD caspase-3, re-
nal function, tubulointerstitial damage, and renal fibrosis
in long-term renal I/R injury. However, in spite of these
different effects of CsA and other immunosuppressants,
changes in inflammation, renal function, tubulointersti-
tial damage, and renal fibrosis were closely correlated
with the expression of 24 kD caspase-3 in all groups. Ra-
pamycin proved to be the drug with the greatest effect
in these areas though this may be due to its high dosage.
Tacrolimus and MMF were lesser than rapamycin, but
both of them are equivalent effectiveness, although they
belong to different categories. We cannot exclusively
conclude that rapamycin is the optimal immunosuppres-
sant for long-term renal I/R injury because of the high
dosage used. The evidence here does at least suggest that
tacrolimus and MMF might prove to be better immuno-
suppressive drugs than CsA.
From a clinical perspective, chronic immunosuppres-
sive treatment needs to be a combination of drugs with
different mechanisms of action to enhance efficacy, re-
duce dosage, and minimize side effects. We have re-
ported that a pan caspase inhibitor, B-D-FMK, inhibited
caspase activity, decreased apoptosis and inflammation,
and subsequently ameliorated renal injury and fibrosis in
an immune-medicated chronic glomerulonephritis model
[44]. It has also been reported that the caspase inhibitor
ZVAD-FMK reduced caspase-3 activity and prevented
the onset of not only apoptosis, but also inflammation
and tissue injury in a renal I/R mouse model, though that
analysis was based on the I/R kidneys of 24 hours [29]. The
evidence from these studies suggests that caspase-3 inhi-
bition may be a useful therapeutic intervention to amelio-
rate the long-term effects of I/R injury and CsA-induced
nephropathy. Caspase-3 inhibition may exert additive or
synergistic effects with various immunosuppressants es-
pecially CsA and minimize their side effects.
CONCLUSION
The mechanism of long-term I/R injury and various im-
munosuppressant treatment may include inflammation,
which is closely correlated with the expression of 24 kD
caspase-3. Active 24 kD caspase-3 may be a major factor
that alters both renal function and morphologic struc-
ture of I/R rat kidneys treated with various immuno-
suppressants.
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